Síntesis de la nueva Guía NICE | 04 AGO 14

Modificación de lípidos en prevención primaria y secundaria

Las recomendaciones del NICE basadas en evidencias para la reducción del riesgo cardiovascular a través de la modificación de los lípidos.

Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease

INDICE: 1. | 2.

National Institute for Health and Clinical Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. (Clinical guideline 67.) 2008. www.nice.org.uk/guidance/CG67.
Baigent C, Blackwell I, Emberson J, Holland LE, Reith C, Bhala N, et al; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med2010;362:1563-74.
Bosch J, Gerstein HC, Dagenais GR, , Díaz R, Dyal L, Jung H, et al; ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18.
Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med2011;365:2255-67.
Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ2008;336:1475-82.
National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. (Clinical guide